AUTL
Price
$2.31
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
617.44M
33 days until earnings call
ERAS
Price
$1.31
Change
+$0.05 (+3.97%)
Updated
Jun 27 closing price
Capitalization
364.02M
40 days until earnings call
Interact to see
Advertisement

AUTL vs ERAS

Header iconAUTL vs ERAS Comparison
Open Charts AUTL vs ERASBanner chart's image
Autolus Therapeutics
Price$2.31
Change-$0.00 (-0.00%)
Volume$2.09M
Capitalization617.44M
Erasca
Price$1.31
Change+$0.05 (+3.97%)
Volume$1.89M
Capitalization364.02M
AUTL vs ERAS Comparison Chart in %
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. ERAS commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a StrongBuy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (AUTL: $2.32 vs. ERAS: $1.28)
Brand notoriety: AUTL and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 69% vs. ERAS: 122%
Market capitalization -- AUTL: $617.44M vs. ERAS: $364.02M
AUTL [@Biotechnology] is valued at $617.44M. ERAS’s [@Biotechnology] market capitalization is $364.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, AUTL is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • AUTL’s TA Score: 5 bullish, 5 bearish.
  • ERAS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than ERAS.

Price Growth

AUTL (@Biotechnology) experienced а +12.62% price change this week, while ERAS (@Biotechnology) price change was -8.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($617M) has a higher market cap than ERAS($364M). AUTL YTD gains are higher at: -1.277 vs. ERAS (-48.805). ERAS has higher annual earnings (EBITDA): -150.24M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. ERAS (305M). ERAS has less debt than AUTL: ERAS (50.8M) vs AUTL (57.7M). AUTL has higher revenues than ERAS: AUTL (9.01M) vs ERAS (0).
AUTLERASAUTL / ERAS
Capitalization617M364M170%
EBITDA-226.02M-150.24M150%
Gain YTD-1.277-48.8053%
P/E RatioN/AN/A-
Revenue9.01M0-
Total Cash517M305M170%
Total Debt57.7M50.8M114%
FUNDAMENTALS RATINGS
AUTL: Fundamental Ratings
AUTL
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AUTLERAS
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TINGX26.090.17
+0.66%
Thornburg International Growth I
QCACX42.60N/A
N/A
Federated Hermes MDT All Cap Core C
PPQMX5.97N/A
N/A
Principal MidCap Growth III R3
MRCEX12.42N/A
N/A
Meridian Hedged Equity C
JDESX45.19N/A
N/A
JPMorgan US Research Enhanced Equity I

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+0.43%
CRSP - AUTL
47%
Loosely correlated
+1.69%
OCUL - AUTL
45%
Loosely correlated
-2.43%
ERAS - AUTL
45%
Loosely correlated
+1.98%
IMCR - AUTL
43%
Loosely correlated
-2.59%
ABEO - AUTL
43%
Loosely correlated
-2.54%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.98%
RVMD - ERAS
57%
Loosely correlated
-1.49%
LRMR - ERAS
54%
Loosely correlated
-2.11%
XNCR - ERAS
53%
Loosely correlated
-3.10%
ATXS - ERAS
52%
Loosely correlated
+2.94%
APGE - ERAS
52%
Loosely correlated
-0.89%
More